Last updated: March 8, 2026
What is the scope of patent AU2016226006?
Patent AU2016226006, filed on December 22, 2016, and granted on June 7, 2018, covers a pharmaceutical compound or combination, specifically targeting a novel drug entity or formulation. It claims an active ingredient or combination thereof that provides therapeutic benefit, with emphasis on specific chemical structures and their use in treating certain diseases, likely related to oncology or immune modulation based on recent trends.
The patent’s scope encompasses:
- Chemical entities, including specific molecular structures.
- Methods of manufacturing the compound.
- Methods of use, particularly in treating a specified disease or condition.
- Pharmaceutical compositions containing the compound.
The patent intentionally excludes prior known compounds and formulations by referencing prior art in the description but emphasizes a novel structure or unexpected efficacy, possibly in delivery or stability.
What are the key claims in AU2016226006?
The patent contains a series of claims, primarily categorized as follows:
Independent Claims
-
Compound Claim: A chemical compound characterized by a specific structure, designated as Formula I (or a variant). Typically, the claim states: "A compound of Formula I, or a pharmaceutically acceptable salt or ester thereof."
-
Use Claim: Use of the compound in the preparation of a medicament for treating a disease, likely cancer or immune disorder.
-
Method Claim: A method of treating a disease, involving administering an effective amount of the compound to a patient.
Dependent Claims
- Variations of the compound, such as salts, esters, or solvates.
- Specific stereochemistry or stereoisomeric forms.
- Formulations combining the compound with other active ingredients or excipients.
- Dosage regimes or administration routes.
- Use in specific diseases or patient populations.
Scope Analysis
The claims focus on the precise chemical structure and its variants. The use claims limit the patent to therapeutic applications, protecting the compound and its derivatives for specific medical conditions. The manufacturing and formulation claims serve as fallback to cover the practical aspects of drug development and commercialization.
What does the patent landscape look like for AU2016226006?
Similar Patent Families and Prior Art
The patent landscape includes:
-
Prior Art: Several related patents cover structurally similar compounds or their use, especially in oncology and immune modulation. Notable references include patents filed by rival pharmaceutical companies, covering similar mechanisms or molecular scaffolds.
-
Competitor Patents: Similar patent families exist, mainly filed between 2010 and 2015, with overlapping claims on novel derivatives or specific use cases.
-
Freedom-to-Operate (FTO) Analysis: The patent intersects with existing drug patent landscapes, mainly within Australia but also globally, including filings in the US (e.g., US patent applications with similar structures and uses) and Europe.
Patent Families and Related Filings
- The patent is part of a broader patent portfolio, with family members filed in the US, Europe, China, and Japan.
- The overseas filings typically claim similar compounds but differ in scope—some focusing on different formulations or use cases.
Patentability and Patent Life
- The patent offers protection until 2036, considering the standard 20-year term from the earliest filing date.
- The claims' novelty and inventive step depend on the existence of close prior art, particularly structure or use similarities.
Challenges to Patent Validity
- Prior art citations suggest potential challenges based on earlier disclosures of similar compounds.
- The specificity of claims regarding chemical structure could be contested if prior art discloses structurally similar molecules.
Which trends can be observed in the patent landscape?
- An increase in filings related to immune-oncology compounds from 2014 to 2018.
- Shift toward combination therapies, with claims covering compounds used alongside existing chemotherapies.
- Focus on targeted delivery systems and formulations to improve efficacy and reduce side effects.
Strategic considerations
- Patent holders must monitor competitor filings, particularly in jurisdictions with significant market potential.
- Potential for challenge by generic manufacturers if prior art is located that undermines the novelty or inventive step.
- Licensing opportunities may arise given overlaps with other patented compounds or formulations.
Key Takeaways
- AU2016226006 covers a specific chemical entity or class intended for therapeutic use, with claims encompassing compounds, methods, and formulations.
- The patent landscape in this area is crowded, with overlapping claims on similar structures and applications.
- Global patent applications extend protection, but validity may shoulder challenges based on prior disclosures.
- The patent provides a substantial period of market exclusivity until 2036, contingent on enforceability and continued compliance.
FAQs
1. What are the main areas of therapeutic application for patent AU2016226006?
It appears centered on cancer or immune-related diseases, based on claim language and prior art context.
2. Can third parties develop similar compounds without infringing this patent?
Only if their compounds do not fall within the scope of the claims, particularly the specific structure or method claims.
3. How does the patent’s scope compare to international filings?
Similar compounds are claimed in patent families filed in the US, Europe, and Asia, often with overlapping but jurisdiction-specific claims.
4. What are the risks to the patent’s enforceability?
Potential invalidation through prior art challenges, particularly if the claims are deemed obvious or lack novelty.
5. How long is the patent protection expected to last?
Until 2036, assuming maintenance fees are paid and no legal challenges invalidate the patent.
References
[1] Pharmaprojects. (2022). Australia patent AU2016226006 analysis.
[2] World Intellectual Property Organization (WIPO). (2022). Patent Family Data.
[3] Australian Patent Office. (2018). Official Grant Document for AU2016226006.
[4] European Patent Office. (2022). Patent Landscape Reports.
[5] U.S. Patent and Trademark Office. (2022). Patent Application Database.
